Abstract
CD79a, a membrane glycoprotein critical for B-cell receptor (BCR) signaling, plays a vital role in B-cell development and immune responses. It serves as a marker for normal and tumor B-cells and is implicated in the progression of various diseases, including B-cell lymphomas, leukemia, autoimmune disorders, and other systemic diseases such as neurological, hematological, and respiratory disorders. This review provides a comprehensive analysis of the discovery, molecular structure, and function of CD79a, along with its regulatory mechanisms at the transcriptional and post-translational levels. CD79a’s involvement in signaling pathways and its potential as a therapeutic target for novel treatments, such as chimeric antigen receptor-T (CAR-T) cell therapy and bispecific antibodies, are also explored. The review highlights emerging therapeutic strategies targeting CD79a, emphasizing its significance in the prognosis of CD79a-related diseases and the ongoing need for further research to optimize clinical interventions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
